ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Latest Articles

05. 08. 2022

Opinion of SÚKL's Department of Clinical Trials on Medicinal Products on Ongoing Clinical Trials in Light of the COVID-19 Epidemiological Situation of 5th August 2022

In view of the coronavirus epidemiological situation that can affect ongoing clinical trials, SÚKL hereby releases statement regarding emergency measures that can apply for...

 

29. 07. 2022

List of reimbursed medicinal products valid as of 1.8.2022

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...

 

15. 07. 2022

Call for experts

Join the European Pharmacopoeia’s community of experts!

 

30. 06. 2022

List of reimbursed medicinal products valid as of 1.7.2022

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...

 

01. 06. 2022

KLH-22 version 5

 

31. 05. 2022

List of reimbursed medicinal products valid as of 1.6.2022

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...

 

30. 05. 2022

Annual Report 2021

Annual Report of the SUKL activities in 2021.

 

24. 05. 2022

Scientific Advice on Marketing Authorisation Issues

Upon request, the Marketing Authorisation Section of the State Institute for Drug Control (hereinafter referred to as the “Institute”) provides Scientific Advice concerning...